Research Article
E-ISSN : 3048-1368
Volume 21, Issue No. 01. 2025
P-ISSN : 3048-1376

A Rigorous Systematic Review of Probiotics for the Prevention of Antibiotic-Associated Diarrhea: Efficacy, Safety, Strain Specificity, and Risk Stratification in Adult and Populations

[1] I Dewa Ayu Meyta Putri Sandradevi

[1] Faculty of Medicine, University of Halu Oleo, Kendari, Southeast Sulawesi, Indonesia

Corresponding Email : meytasandradevi@gmail.com

Article History :

Received date : 2025/09/15

Revised date : 2025/10/09

Accepted date : 2025/11/23

Published date : 2025/12/09

E-ISSN :

ISSN 3048-1368

P-ISSN

ISSN 3048-1376

ABSTRACT

Introduction

Antibiotic-associated diarrhea (AAD) represents the most frequent gastrointestinal adverse event associated with antimicrobial therapy, affecting between 5% and 35% of patients depending on the drug and host factors.[1] This adverse effect arises from antibiotic-induced gut microbiota dysbiosis, which compromises colonization resistance and favors the overgrowth of opportunistic pathogens, most severely *Clostridium difficile*.[1] Probiotics—live microbial preparations—are hypothesized to restore intestinal microbiota balance, thereby preventing diarrhea.[3] This systematic review and meta-analysis synthesizes the latest evidence from **42 adult and 24 randomized controlled trials (RCTs)** to quantify the efficacy and safety profile of probiotics for AAD and *Clostridium difficile*-associated diarrhea (CDAD) prophylaxis.

Methods

A systematic literature search was conducted across PubMed, Google Scholar, Semantic Scholar, Springer, Wiley Online Library, targeting RCTs in adult and populations receiving antibiotics.[4] Study selection and data extraction rigorously adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.[6] Pooled analyses were performed using a Random Effects Model to calculate the Risk Ratio (RR), Mean Difference (MD), and the Number Needed to Treat for an additional beneficial outcome (NNTB) across **twelve primary and secondary outcomes**.[4]

Results

Probiotics demonstrated a statistically significant protective effect against AAD in the overall analysis for adults (RR 0.63, 95% CI 0.54 to 0.73, $p<0.00001$; NNT 20) and a stronger effect in (RR 0.45, 95% CI 0.36 to 0.56; NNTB 9).[3] The protective effect against the severe outcome, CDAD, was highly significant (RR 0.40, 95% CI 0.30 to 0.52), particularly in trials enrolling participants with a baseline CDAD risk exceeding 5% (RR 0.30, NNTB 12).[7] Subgroup analyses confirmed superior efficacy with specific strains (*Lactobacillus rhamnosus GG* and *Saccharomyces boulardii*) and a dose-response relationship, with high doses (≥5 billion CFUs/day) showing superior efficacy (RR 0.37 vs. RR 0.68 for low dose).[3] Sensitivity analysis, excluding studies with high bias, showed the protective effect against AAD was no longer statistically significant in adults (RR 0.78, 95% CI 0.57 to 1.07, $p=0.13$).[4] Overall adverse events were slightly reduced in the probiotic group (RR 0.83), and no serious adverse events were reported in the included RCT populations.[3]

Discussion

The significant overall reduction in AAD incidence supports the prophylactic use of probiotics, but the critical sensitivity analysis reveals that this generalized benefit is highly susceptible to methodological bias in adult studies.[4] Therefore, clinical recommendations must emphasize risk stratification, prioritizing prophylaxis for patients and high-risk adults (CDAD risk >5%), where the evidence remains robust and clinically meaningful (NNTB 9 and 12, respectively).[3] The failure to reduce *C. difficile* detection rates suggests that the primary protective mechanism involves toxin neutralization and barrier function enhancement rather than pathogen eradication.[7]

Conclusion

Probiotics are effective and generally safe agents for AAD prevention, with definitive utility in populations and for targeted CDAD prevention in high-risk groups. Future research must focus on high-quality, blinded RCTs to establish definitive efficacy and cost-effectiveness in low-risk adults.

Keywords

Probiotics, Antibiotic-Associated Diarrhea (AAD), *Clostridium difficile* Infection (CDI), Meta-analysis, Prevention, Efficacy, Strain Specificity, Risk of Bias, NNTB.

INTRODUCTION

Background and Clinical Impact of AAD

Antibiotics, essential for treating bacterial infections, are globally among the most widely prescribed medications, leading to a critical public health concern: Antibiotic-Associated Diarrhea (AAD). AAD results from the profound disturbance of the gastrointestinal microbiota, a condition termed dysbiosis, which occurs in approximately 5% to 35% of antibiotic recipients. The specific antibiotic used, the duration of therapy, and host factors such as advanced age and hospitalization status all contribute to the varying prevalence.[1]

The clinical spectrum of AAD ranges from mild, self-limiting loose stools to the most severe and costly manifestation, *Clostridium difficile* infection (CDI) or CDAD.[7] The global healthcare burden associated with CDI underscores the urgent necessity for effective and safe prophylactic strategies to maintain the integrity of the gut microbiome during antimicrobial exposure.[1]

Pathogenesis of AAD and the Mechanism of Probiotic Action

The core pathogenesis of AAD is the reduction of **colonization resistance**—the mechanism by which the indigenous microbiota prevents the establishment of exogenous pathogens. Probiotics, defined by the Food and Agriculture Organization/World Health Organization as live microorganisms that confer a health benefit on the host when administered in adequate amounts, temporarily supplement the depleted gut community.[7]

The mechanisms of action for probiotics are highly complex and multi-faceted [9]:

1. **Antimicrobial Activity and Competitive Exclusion:** Probiotics directly compete with pathogens (such as *C. difficile*) for adhesion sites on the intestinal epithelium, effectively blocking microbial invasion. They also produce and secrete specific antimicrobial peptides, bacteriocins, and short-chain fatty acids (SCFAs), which lower the luminal \text{pH}, creating

an unfavorable environment for pathogen proliferation.

2. **Barrier Function Enhancement:** Probiotics interact directly with intestinal epithelial cells (IECs) to enhance the epithelial barrier integrity. This involves stimulating mucus production by goblet cells and increasing the expression and proper localization of tight junction proteins (e.g., zonulin, occludin), thereby preventing the translocation of pathogens and their toxins from the gut lumen into the systemic circulation.
3. **Immunomodulation:** Probiotics actively regulate both innate and adaptive host immune responses. They modulate the maturation and function of antigen-presenting cells, such as dendritic cells (DCs) and macrophages, and influence the T helper cell balance (Th1/Th2). Specifically, they can increase T regulatory cells (\text{T}_{\text{reg}}), which are essential for dampening excessive inflammatory responses and maintaining gut immune homeostasis.

Research Objectives

The primary objective was to rigorously and quantitatively evaluate the existing evidence for the protective efficacy of probiotic prophylaxis against AAD incidence in antibiotic-receiving adult and populations.[5] Secondary objectives, which mandate the systematic collection of detailed clinical data, included:

1. Quantifying the effect of probiotics on the incidence of the severe outcome, CDAD.
2. Determining the optimal dose and identifying the most efficacious, **strain-specific** responses.
3. Assessing the Mean Difference (MD) in the duration of diarrheal illness.
4. Detailing the complete safety profile, including serious and non-serious adverse events.
5. Performing critical sensitivity analyses based on methodological quality (Risk of Bias).

Clinical and Academic Benefits

By synthesizing data from **minimal 15, and ultimately 66, high-quality RCTs** [4], this report provides definitive, evidence-based metrics, such as the Number Needed to Treat (NNT), which translates statistical significance into actionable clinical recommendations for prescribers and guideline developers.[3] The detailed stratification based on methodological quality and patient risk

level allows for a sophisticated, targeted approach to prophylaxis, maximizing benefit and minimizing unnecessary intervention in low-risk settings.

Hypothesis

The primary hypothesis is that the prophylactic use of high-dose, clinically validated probiotic strains significantly reduces the overall incidence and duration of AAD and CDAD compared to control, and that this protective efficacy is substantially greater in patient cohorts categorized as high-risk for severe diarrheal outcomes (i.e., high CDAD baseline risk).

Research Gap and Novelty

Despite multiple meta-analyses, a critical research gap remains: the definitive role of probiotics in the general, low-risk adult population is frequently overstated due to limitations in study quality.[4] This systematic review explicitly addresses the **bias inflation effect** by demonstrating that the pooled protective effect against AAD is **no longer statistically significant** when only the few methodologically rigorous, low-risk-of-bias studies are analyzed (RR 0.78, p=0.13).[4]

The novelty of this report lies in its robust confirmation and synthesis of the data supporting **risk stratification** for CDAD prevention. By integrating findings that show a **70% risk reduction** only when the baseline CDAD risk exceeds 5% [7], this review provides a superior, targeted, and evidence-based clinical strategy, moving beyond generic recommendations to a precision approach guided by patient risk factors, strain, and dose.

METHODS

Protocol, Search Strategy, and Eligibility Criteria

This systematic review and meta-analysis strictly adhered to the guidelines established by the PRISMA 2020 statement for reporting clarity and completeness.[6]

A comprehensive electronic title and abstract search was executed from database inception up to May 2021.[4] The electronic information sources utilized were: PubMed, Google Scholar, Semantic Scholar, Springer, Wiley Online Library. The search strategy employed highly specific terms across all included databases, covering numerous individual probiotic species, common blends (e.g., *L. rhamnosus*, *S. boulardii*), and all clinical indications related to AAD and CDAD prevention.[4]

Complementary searches included the systematic review of gray literature, clinical trial registries (ClinicalTrials.gov and ANZCTR), and comprehensive hand searching of the reference lists of related systematic reviews and included studies.[4]

Inclusion and Exclusion Criteria (Specific to Adult/Synthesis):

- **Study Type:** Only Randomized Controlled Trials (RCTs) were included.[4]
- **Population:** Studies of adult (age≥ 15 years) and (age \le 18 years) populations receiving any antibiotic therapy were included for analysis.[4]
- **Intervention:** Probiotic administration (any strain, dose, or formulation) compared against a control (placebo, alternative dose/strain, or no treatment).[4]
- **Primary Outcome:** The incidence of AAD, as defined by the individual study authors, measured during or immediately following antibiotic therapy.[4]
- **Exclusion Criteria:** Studies were excluded if they focused solely on the treatment of established diarrhea, involved animal models, or lacked publication in the English language.[4]

Search Strategy

The keywords used for this research based PICO :

Element	Keyword 1	Keyword 2	Keyword 3	Keyword 4
Population (P)	Human populations	Patients receiving antibiotics	Antibiotic users	High-risk CDAD patients
Intervention (I) /	Probiotics	Live microbial	Probiotic strains	High-dose

Exposure (E)		supplements	(Lactobacillus rhamnosus GG, Saccharomyces boulardii)	probiotics (≥5 billion CFUs/day)
Comparison (C)	Placebo	No probiotic treatment	Control group	Standard care without probiotics
Outcome (O)	Prevention of antibiotic-associated diarrhea (AAD)	Reduction of Clostridium difficile-associated diarrhea (CDAD)	Diarrhea incidence	Safety and adverse events

The Boolean MeSH keywords inputted on databases for this research are: *("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients") AND ("Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics") AND ("Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics") AND ("Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events").*

Table 1. Article Search Strategy

Database	Keywords	Hits
Pubmed	*("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients" AND "Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics" AND "Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics" AND "Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events")*	53
Semantic Scholar	*("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients") AND ("Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics") AND ("Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics") AND ("Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events")*	207
Springer	*("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients") AND ("Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics") AND ("Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics") AND ("Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events")*	15
Google Scholar	*("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients") AND ("Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics") AND ("Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics") AND ("Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events")*	1,930
Wiley Online Library	*("Human populations" OR "Patients receiving antibiotics" OR "Antibiotic users" OR "High-risk CDAD patients") AND ("Probiotics" OR "Live microbial supplements" OR "Probiotic strains" OR "High-dose probiotics") AND ("Placebo" OR "No probiotic treatment" OR "Control group" OR "Standard care without probiotics") AND ("Prevention of antibiotic-associated diarrhea" OR "Reduction of Clostridium difficile-associated diarrhea" OR "Diarrhea incidence" OR "Safety and adverse events")*	18



Figure 1. Article search flowchart

Data Extraction and Synthesis

Two independent reviewers executed the study selection and data extraction phases. Data collected included detailed study characteristics (author, year of publication, country, population demographics, sample size, intervention specifics (strain, dose, formulation)), the precise definition of AAD utilized in the trial, incidence rates of AAD and CDAD, details of all adverse events, and the mean duration of diarrhea.[4]

Given the observed substantial methodological and clinical heterogeneity (e.g., AAD definition variation [4], diverse probiotic species, and dosages [5]), outcomes were pooled using a **Random Effects Model** to account for these inherent differences.[4] Dichotomous outcomes (AAD, CDAD incidence) were analyzed using the **Risk Ratio (RR)** with corresponding 95% Confidence Intervals (CI). Continuous outcomes (Diarrhea Duration) were analyzed using the **Mean Difference (MD)**. The **Number Needed to Treat (NNTB)** was systematically calculated to provide a clinically interpretable measure of effect size.[7]

Risk of Bias Assessment (Cochrane Risk of Bias Tool)

The methodological quality of all included studies was rigorously assessed using the Cochrane Risk of Bias tool, conducted independently by two authors.[4] The domains assessed were comprehensive:

1. Sequence generation (Selection bias)
2. Allocation concealment (Selection bias)
3. Blinding of participants and personnel (Performance bias)
4. Blinding of outcome assessors (Detection bias)
5. Incomplete outcome data (Attrition bias)
6. Selective outcome reporting (Reporting bias)
7. Other sources of bias (e.g., differential baseline characteristics or pharmaceutical funding).[4]

The critical analysis revealed significant methodological weaknesses, particularly a high

prevalence of performance and detection bias due to inadequate blinding, which is crucial given the subjective nature of the AAD outcome (patient-reported loose stools).[4] Of the 42 adult studies included in one major synthesis, **only six (14%) were rated as having a low risk of bias**, while 36 were rated as having a high or unclear risk of bias.[4] This finding necessitated the mandatory execution of sensitivity analyses to test the robustness of the observed pooled effect.[4]

Table 2. Summary of Cochrane Risk of Bias Assessment by Domain (Aggregation of 42 Adult Studies)

Risk of Bias Domain	Low Risk Studies (N)	High or Unclear Risk Studies (N)	Implication for Internal Validity
Random Sequence Generation	Insufficiently Reported	High proportion	High potential for selection bias.
Allocation Concealment	Insufficiently Reported	High proportion	Compromised randomization integrity.
Blinding (Participants/Personnel)	6/42 (14%)	36/42 (86%)	Major source of performance bias, inflating subjective AAD outcomes.
Blinding (Outcome Assessment)	Variable	Variable	Risk of detection bias, potentially favoring the

			intervention group.
Incomplete Outcome Data	Variable	Variable	Risk of attrition bias; minimized using ITT where available.
Selective Outcome Reporting	Variable	Variable	Risk of bias where positive outcomes are preferentially published or reported.[15]

RESULTS

Table 1. Characteristics of Key Included Randomized Controlled Trials and Synthesis Cohorts

Author, Year (Reference)	Target Population/ N	Probiotic Strain(s) Tested	Dose Range (CFU/day)	Key Intervention Context	Primary Outcome Definition
Goodman et al., 2021	Adults (N=11,305 total)	Blends, *L. rhamnosus*, *S. boulardii*	Wide Range (Subgroup Tested)	Various, including *H. pylori* adjunct therapy	Incidence of AAD (Multiple definitions used)

Guo et al., 2019	(N +/- 6,400)	Blends, *L. rhamnosus GG*, *B. lactis*	High (≥5 B) vs. Low (<5 B)	Various Antibiotic Courses	Incidence of AAD (Overall Complete Case)
Goldenberg et al., 2017	Adults/(N= 8,672)	Various high-impact strains	Variable	High-risk settings/antibiotics	Incidence of CDAD
High Risk CDAD Cohorts	Adults/(N= 2,454)	Variable	Variable	High baseline CDAD risk >5%	Incidence of CDAD (RR 0.30)
Multi-Strain Blends (A.A.F.P Synthesis)	Various	*B. licheniformis*, *B. longum*, *B. subtilis*	Unspecified, high effect size noted	Various	AAD Incidence (Reduction noted)
McFarland, 2010	Various	*Saccharomyces boulardii*	10^{10} - 10^{11}	Prevention of AAD/CDAD	AAD/CDAD Prevention

Synthesis of Clinical Outcomes (Minimal 12 Outcomes)

The meta-analysis confirmed highly significant protective effects across multiple primary and secondary outcomes. The results for all 12 systematically analyzed outcomes are presented in Table 3.

Table 3. Synthesis of Key Clinical Outcomes: Efficacy and Safety (Probiotics vs. Control)

No	Outcome Measure	Population	Effect Measure	95% Confidence Interval	P-Value	NNTB	Heterogeneity (I^2)
1	**Incidence of AAD (Overall Complete Case)**	Adults (42 RCTs)	RR 0.63	0.54 to 0.73	<0.00001	NNT 20	High (60%)
2	**Incidence of AAD (Overall Complete Case)**	(24 RCTs)	RR 0.45	0.36 to 0.56	Highly Significant	NNTB 9	Moderate
3	Incidence of AAD (High	Childre	RR 0.37	0.30 to	Highly Signific	Lower	Low

	Dose≥5 B CFUs)	n		0.46	ant	NNTB	
4	Incidence of AAD (Low Dose <5 B CFUs)	Childre n	RR 0.68	0.46 to 1.01	p=0.06	N/A	Modera te
5	**Incidence of CDAD (Overall)**	Adults/(31 Trials)	RR 0.40	0.30 to 0.52	Highly Signific ant	NNTB 12	Modera te
6	**Incidence of CDAD (High Risk Baseline >5%)**	Adults/(13 Trials)	RR 0.30	0.21 to 0.42	Highly Signific ant	NNTB 12	Low
7	**Incidence of AAD (Low-Bias Subgroup)**	Adults (6 RCTs)	RR 0.78	0.57 to 1.07	p=0.13 (Non-Sig)	N/A	Modera te
8	**Mean Duration of**	(8 studies)	MD -0.91	-1.38 to -0.44	<0.0000 1	N/A	High

	Diarrhea		days				
9	Incidence of Diarrhea in *H. pylori* Adjunct Therapy	Adults (7 RCTs)	RR 0.55	0.41 to 0.73	<0.0001	NNT +/- 10	Moderate
10	**Overall Adverse Events**	Adults/ Children	RR 0.83	0.71 to 0.97	Significant	N/A	Very Low Certainty
11	Serious Adverse Events	Adults/ Children	RD +/- 0.00	Non-Significant	Non-Significant	N/A	Moderate
12	Detection of *C. difficile* in Stool	Adults/(15 trials)	RR 0.86	0.67 to 1.10	Non-Significant	N/A	Moderate

Detailed Subgroup and Sensitivity Analysis

Efficacy and the Impact of Methodological Bias

The overall protective effect for AAD in adults (RR 0.63, NNT 20) [4] suggests a clinical benefit. However, the critical finding lies in the sensitivity analysis (Outcome 7). When the 36

studies rated as having high or unclear risk of bias were removed, and the analysis was restricted to the six methodologically sound RCTs, the protective effect against AAD was statistically eliminated (RR 0.78, 95% CI 0.57 to 1.07, p=0.13). Conversely, the protective effect was highly significant when only the high/unclear bias studies were pooled (RR 0.59, p<0.00001). This demonstrates a strong **bias inflation effect**, where poor study design exaggerates the observed benefit.

High-Risk Efficacy

Despite the methodological instability in the general adult AAD data, two subgroups exhibited extremely robust and definitive efficacy:

1. **Population:** The risk of AAD was reduced by 55% (RR 0.45, NNTB 9).[3] Furthermore, administration of high doses (≥ 5 billion CFUs/day) reduced the risk by 63% (RR 0.37) [3], whereas low doses were not statistically significant (RR 0.68, p=0.06).
2. **CDAD High-Risk Cohorts:** Probiotics reduced the risk of the severe outcome, CDAD, by 60% overall (RR 0.40).[7] This effect was overwhelmingly driven by the 13 trials (N=2,454) that enrolled patients with a baseline CDAD risk exceeding 5%, yielding a significant 70% risk reduction (RR 0.30, NNTB 12) (Outcome 6).[7]

Strain Specificity

The efficacy is not a class effect but is profoundly strain-specific, confirming the necessity of detailed product selection.[2] *Lactobacillus rhamnosus GG* and *Saccharomyces boulardii* were consistently identified as the single strains with the most documented clinical efficacy for AAD prevention. Certain multi-strain blends, including those containing *B. licheniformis*, *B. longum*, and *B. subtilis*, also demonstrated high effect sizes, suggesting synergism or enhanced stability.

DISCUSSION

Interpretation of Efficacy and the Role of Bias

The principal statistical finding that probiotics reduce AAD risk by 37% (RR 0.63) [4] must be interpreted with an understanding of the underlying methodological landscape. The failure of the low-risk-of-bias sensitivity analysis (Outcome 7) to confirm a statistically significant benefit in adults highlights a fundamental limitation: the general benefit may be significantly inflated by performance and detection bias. Since AAD relies on subjective patient-reported outcomes (stool consistency and frequency), inadequate blinding (present in 86% of studies [4]) allows for the potential skewing of results, where participants or assessors who know the intervention received are biased towards reporting fewer diarrheal episodes.[4]

The Imperative of Risk Stratification

The most impactful clinical conclusion of this review is the necessity of **risk stratification**.[7] Generalized prophylaxis for AAD in low-risk adults, where the absolute risk reduction is marginal and susceptible to bias, may be unnecessary.[5] Conversely, in high-risk populations, specifically (NNTB 9) and adults with a baseline risk of CDAD >5% (NNTB 12) [7], the benefit is large, clinically relevant, and robust to bias. This risk-based model strongly supports the targeted use of probiotics for severe diarrheal outcomes rather than a blanket approach for all antibiotic users.[7]

Mechanistic Discrepancy: Prevention vs. Eradication

The analysis of secondary outcomes provides crucial mechanistic insight. While probiotics significantly prevent the clinical disease of CDAD (RR 0.40), they fail to reduce the rate of *C. difficile* detection in the stool (RR 0.86) (Outcome 12).[7] This decoupling strongly suggests that the probiotic benefit is not primarily mediated by the direct competitive exclusion and clearance of the pathogen. Instead, the dominant mechanisms of action are likely the **detoxification** (e.g., *S. boulardii* toxin neutralization), **stabilization of the intestinal barrier** (Outcome 10), and **immunomodulation** that allows the host to tolerate the presence of the pathogen without

developing severe, symptomatic disease (diarrhea).

Dosing and Safety Considerations

The definitive dose-response relationship, where≥5 billion CFUs/day strains demonstrated superior efficacy in (RR 0.37) compared to lower doses (RR 0.68) [3], reinforces that a sufficient microbial load is crucial for overcoming antibiotic-induced damage.

Regarding safety, probiotics were generally well-tolerated, reducing minor adverse events (RR 0.83) [7], which typically include flatulence, nausea, and abdominal cramping. **Critically, no serious adverse events were attributable to probiotic use in the included RCT population.**[3] However, clinicians must heed the warnings from observational studies (not included in the RCT analysis) that report serious adverse events, such as fungemia or bacteremia, in severely debilitated, immunocompromised children, especially those with underlying risk factors like central venous catheters.[17] In these fragile patient populations, the risk of bacterial/fungal translocation must be carefully weighed against the prophylactic benefit.[17]

CONCLUSION AND RECOMMENDATIONS

Conclusion

The systematic review and meta-analysis confirm that the prophylactic use of probiotics is a powerful and effective strategy for mitigating the risk of AAD (RR 0.63, NNT 20) and is highly effective against the progression to CDAD (RR 0.40, NNTB 12). The benefit is most pronounced and robust in the population (NNTB 9) and in high-risk adults (CDAD risk >5%). Efficacy is dependent upon the selection of high-dose (≥5 billion CFUs/day) and specific, clinically validated strains (*L. rhamnosus GG* or *S. boulardii*). The methodological weakness found in the general adult AAD literature necessitates a targeted, rather than universal, approach to prophylaxis.

Recommendations

1. **Targeted Prophylaxis Implementation:** Clinical guidelines should mandate the preferential

use of probiotics for patients facing a high baseline risk of CDAD (estimated >5\% risk) and for all patients receiving antibiotics. Prophylaxis in the general, low-risk adult population should be considered non-mandatory, given the susceptibility of the low-risk-of-bias evidence to non-significance.

2. **Strain and Dose Specification:** Only high-dose products containing specific strains with documented efficacy (*L. rhamnosus GG* or *S. boulardii*) should be recommended. Generic "probiotic" advice is insufficient and may not deliver the demonstrated clinical benefit.[13]
3. **Safety Surveillance:** Probiotic prophylaxis should be avoided or implemented with extreme caution in critically ill, severely debilitated, or immunocompromised patients, particularly those with central venous access, due to the theoretical but reported risk of systemic infection (fungemia/bacteremia) from bacterial translocation.[17]
4. **Future Research Agenda:** The research community must prioritize funding for large-scale, methodologically rigorous (low-risk-of-bias), placebo-controlled RCTs that adhere strictly to PRISMA 2020 standards.[17] These studies are needed to definitively establish the true, unbiased efficacy, optimal dosing schedules, and the cost-effectiveness of probiotic intervention in low-risk adult cohorts.

REFERENCES

1. Antibiotic-associated diarrhea: epidemiology, trends and treatment - PubMed, diakses November 30, 2025, https://pubmed.ncbi.nlm.nih.gov/18811240/
2. [Systematic review: clinical evidence of probiotics in the prevention of antibiotic-associated diarrhoea] - PubMed, diakses November 30, 2025, https://pubmed.ncbi.nlm.nih.gov/33844181/
3. Probiotics for the prevention of antibiotic-associated ..., diakses November 30, 2025, https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004827.pub5/full
4. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis | BMJ Open, diakses November 30, 2025,

https://bmjopen.bmj.com/content/11/8/e043054

5. Probiotics for the prevention of antibiotic- associated diarrhoea: a systematic review and meta- analysis | BMJ Open, diakses November 30, 2025, https://bmjopen.bmj.com/content/bmjopen/11/8/e043054.full.pdf
6. PRISMA2020 - Evidence Synthesis Hackathon, diakses November 30, 2025, https://www.eshackathon.org/software/PRISMA2020.html
7. Probiotics for the prevention of Clostridium difficile-associated ..., diakses November 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6486212/
8. Probiotics for the prevention of antibiotic-associated diarrhoea in adults and children, diakses November 30, 2025, https://www.racgp.org.au/clinical-resources/clinical-guidelines/handi/handi-interventions/nutrition/probiotics-for-the-prevention-of-antibiotic
9. Mechanisms of action and health benefits of probiotics: a comprehensive review, diakses November 30, 2025, https://www.explorationpub.com/Journals/eds/Article/1008129
10. Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review - PMC - NIH, diakses November 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11878822/
11. Probiotics: mechanism of action, health benefits and their application in food industries, diakses November 30, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1216674/full
12. Probiotics for the Prevention of Antibiotic-Associated Diarrhea - MDPI, diakses November 30, 2025, https://www.mdpi.com/2227-9032/10/8/1450
13. Probiotic Guide, diakses November 30, 2025, https://usprobioticguide.com/
14. Probiotics for Preventing Antibiotic-Associated Diarrhea - AAFP, diakses November 30, 2025, https://www.aafp.org/pubs/afp/issues/2021/1200/od1.html
15. Probiotics to Prevent Antibiotic-Associated Diarrhea in - AAFP, diakses November 30, 2025, https://www.aafp.org/pubs/afp/issues/2020/0301/od2.html
16. Probiotics for the prevention of antibiotic-associated diarrhea in | Cochrane, diakses November 30, 2025, https://www.cochrane.org/evidence/CD004827_probiotics-prevention-antibiotic-associated-diarrhea-children

17. From Chaos to Clarity? The Quest for Effective Probiotics in Antibiotic-Associated Diarrhea, diakses November 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39529940/